Cannabis Rescheduling: What Schedule III Actually Changes, and What It Doesn’t

The federal rescheduling process has moved further than at any point in 50 years. For cannabis operators, patients, and researchers, the practical consequences range from substantial tax relief to no change at all — depending on the question you’re asking.

Cannabis rescheduling refers to the federal process of moving cannabis from Schedule I to Schedule III under the Controlled Substances Act. It is the most significant shift in U.S. federal drug policy in over half a century, and it’s also one of the most misread. A common assumption holds that moving cannabis from Schedule I to Schedule III effectively legalizes it federally. It does not. Schedule III status would confirm that cannabis has recognized medical uses and a lower abuse potential relative to Schedule I or II substances, but federal criminal law would continue to apply to cannabis outside lawfully authorized channels.

Understanding the gap between what rescheduling achieves and what it leaves intact matters for patients, clinicians, and cannabis businesses across the country.

Important Note

As of April 2026, cannabis has not been formally rescheduled. The DEA published a proposed rule in May 2024. President Trump signed an executive order in December 2025 directing the Department of Justice to expedite the process. A final rule has not yet been issued. Rescheduling takes legal effect only when the DEA finalizes the rule.

How Cannabis Rescheduling Reached This Point

The path to rescheduling began in October 2022, when President Biden directed federal agencies to review cannabis’s Schedule I classification. In 2023, the Department of Health and Human Services concluded that cannabis has a “currently accepted medical use in treatment in the United States” and a lower abuse potential than Schedule I or II substances, citing more than 30,000 healthcare professionals authorized to recommend cannabis for patients across 43 U.S. jurisdictions, serving more than six million registered patients for at least 15 medical conditions.

The Department of Justice issued a proposed rule for marijuana rescheduling in May 2024. Progress stalled through most of 2025 amid competing procedural and political pressures, including a provision in a House spending bill that would have barred federal funds for rescheduling, which the Senate removed in January 2026. President Trump’s December 2025 executive order directed DOJ to accelerate the stalled process, framing faster rescheduling as a research and economic priority. DOJ may finalize the May 2024 proposed rule, or issue a new proposed rule; either path requires completing the administrative record and addressing public comments before a final rule takes effect.

The Science Behind the Cannabis Rescheduling Recommendation

The HHS recommendation rested on a restructured legal framework, not a new body of clinical evidence. Federal health officials applied a novel two-part test: whether there is “widespread current experience with medical use” by licensed practitioners, and whether “some credible scientific support” exists for at least one medical use. This departed from the DEA’s prior five-part test, under which FDA conducted an eight-factor scheduling analysis in 2016 and reached the opposite conclusion.

The FDA’s 2023 review found mixed effectiveness findings across indications, with the strongest evidence base for pain, particularly neuropathic pain. This is not an FDA approval of botanical cannabis as a pharmaceutical drug. It is a recognition that clinical practice has outpaced regulation, and that some credible evidence supports medical use in specific conditions.

What Cannabis Rescheduling Would Actually Change

The 280E Tax Burden

The most immediate and concrete benefit of rescheduling is 280E relief. Section 280E of the Internal Revenue Code bars businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses. Because cannabis is currently Schedule I, state-legal cannabis operators face effective federal tax rates that can exceed 70%. Moving cannabis to Schedule III removes it from 280E’s scope entirely, allowing operators to deduct standard expenses like payroll, rent, and cost of goods.

The scale of accumulated 280E costs is substantial. Whitney Economics estimated that the cannabis industry paid more than $15 billion in excess 280E-related federal taxes between 2018 and 2025, with $2.24 billion in excess taxes in 2025 alone. A typical dispensary stands to save approximately $268,000 per year if rescheduling finalizes. This relief applies going forward; it is not retroactive.

Research Access

Schedule I status has created compounding barriers to cannabis research. Scientists need a special DEA license to study Schedule I substances, navigate review processes involving NIDA, the FDA, and the DEA simultaneously, and work with federally approved cannabis sources that often do not reflect commercial product diversity. These constraints have blocked trial enrollment and contributed to a research base dominated by observational studies rather than the randomized controlled trials used to evaluate other drugs.

Rescheduling would remove some of these barriers, particularly those tied specifically to Schedule I status. DEA registration requirements, institutional review processes, and sourcing constraints will persist. The research improvements rescheduling enables may take years to appear in usable clinical evidence.

What Cannabis Rescheduling Leaves Unresolved

Schedule III status, on its own, leaves several central issues unresolved:

Adult-use cannabis remains a federal offense. Schedule III cannabis status reflects accepted medical use and reduced abuse potential. It does not authorize recreational use, preempt state law, or bring state-licensed cannabis markets into federal compliance.
Banking access is not addressed. Cannabis businesses would continue to face restricted access to banking services without congressional action, such as passage of the SAFER Banking Act, which would provide statutory protections for financial institutions serving state-legal cannabis operators.
Criminal penalties largely remain. While some CSA penalties are lower for Schedule III violations, mandatory minimum sentences tied to cannabis quantity would stay in place. Federal collateral consequences in housing, immigration, and firearms ownership would remain largely intact.
Past harms go unaddressed. Rescheduling does not expunge records or repair the harms of criminalization, which has disproportionately affected Black and brown communities. Advocates note that accelerated consolidation could follow rescheduling without equity protections built into any subsequent regulatory framework.

Cannabis Rescheduling vs. Descheduling: What’s the Difference?

A peer-reviewed analysis of all 42,000-plus public comments submitted to the DEA during the rulemaking process found that 71% of respondents supported descheduling cannabis, not rescheduling. The share favoring descheduling grew among respondents who submitted comments later in the process, suggesting that broader public engagement pushed toward a more comprehensive reform position.

The distinction matters. Descheduling removes cannabis from the Controlled Substances Act entirely. States currently regulate alcohol and tobacco as they see fit because those substances fall outside the CSA. Cannabis descheduling would grant states equivalent authority. Absent that, producers, dispensaries, and consumers operating within state frameworks would still face potential federal exposure.

Cannabis rescheduling to Schedule III represents a meaningful step. The 280E relief alone will shift the economic viability of scores of state-legal cannabis businesses. The research barriers it removes could, over time, generate the clinical evidence that patients and clinicians have lacked. What Schedule III cannot do is resolve the fundamental conflict between federal drug law and the cannabis regulatory frameworks that 38 states have built. That resolution requires congressional action, and none is currently on a clear legislative path.

Frequently Asked Questions

Does cannabis rescheduling to Schedule III make it federally legal?

Cannabis rescheduling to Schedule III does not make cannabis federally legal. Schedule III status reflects accepted medical use and a lower abuse potential than Schedule I or II substances, but criminal penalties and federal regulatory controls continue to apply to cannabis outside lawfully authorized channels. Recreational use remains a federal offense.

What is Section 280E and how does rescheduling affect it?

Section 280E of the Internal Revenue Code bars businesses that traffic in Schedule I or II controlled substances from deducting ordinary business expenses. Because cannabis is currently Schedule I, state-legal cannabis operators face effective federal tax rates that can exceed 70%. Moving cannabis to Schedule III removes it from 280E’s scope, allowing operators to deduct standard business expenses. Whitney Economics estimated the industry paid more than $15 billion in excess 280E-related federal taxes between 2018 and 2025.

Has cannabis actually been rescheduled yet?

As of April 2026, cannabis has not been formally rescheduled. The DEA issued a proposed rule in May 2024. President Trump signed an executive order in December 2025 directing the Department of Justice to expedite the process. A final rule has not been published. Rescheduling takes legal effect only when the DEA finalizes the rule.

What is the difference between rescheduling and descheduling cannabis?

Rescheduling moves cannabis from one controlled substance schedule to another — in this case, from Schedule I to Schedule III. Federal controlled substances law still applies. Descheduling removes cannabis from the Controlled Substances Act entirely, giving states the same regulatory authority over cannabis that they currently hold over alcohol and tobacco. A peer-reviewed analysis of public comments found that 71% of respondents supported descheduling rather than rescheduling.

Was this useful for you? Yes 2 No 0

Why not?